GlassScriptPhysician profile
David H Beck
NPI 1679646350
$8,321.08
in general payments reported to CMS, 2019-2025
30 companies · $738 in 2025
The $738 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,387 · 2022: $2,068 · 2023: $1,042 · 2024: $1,086 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,866.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,182.28 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,060.24 | 2021-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $980.63 | 2021 | |
| Abbvie INC. | $853.80 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $711.55 | 2021-2025 | Jardiance |
| Amgen INC. | $667.54 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $531.46 | 2021-2025 | Mounjaro, Amyvid, Zepbound |
| Abbott Laboratories | $389.14 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $299.09 | 2021-2022 | |
| Pfizer INC. | $292.92 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.62 | 2021-2024 | Trulance, Xifaxan |
| Boston Scientific Corporation | $186.73 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $154.24 | 2021-2022 | |
| Genzyme Corporation | $121.83 | 2025 | |
| Janssen Pharmaceuticals, INC | $81.34 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $74.90 | 2021-2023 | |
| Exact Sciences Corporation | $71.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $71.42 | 2021-2023 | Seglentis |
| Vanda Pharmaceuticals INC. | $66.99 | 2021-2023 | Hetlioz |
| Merck Sharp & Dohme LLC | $59.24 | 2022-2023 | Belsomra |
| Inspire Medical Systems, INC. | $56.58 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $47.42 | 2022 | |
| Eisai INC. | $36.59 | 2021-2022 | |
| Nevro Corp. | $23.30 | 2021 | |
| Sanofi Pasteur INC. | $20.84 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.29 | 2023 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $18.67 | 2022 | |
| Celltrion USA INC. | $18.14 | 2024 | Vegzelma |
| Amarin Pharma, INC. | $14.84 | 2022 | |
| Vistapharm, INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.